ID   K562/HHT
AC   CVCL_A9BR
DR   Wikidata; Q108820618
RX   CelloPub=CLPUB00641;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; HHT).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 29-06-23; Version: 5
//
RX   CelloPub=CLPUB00641;
RA   Liu Y., Chen C.-Y., Kong D.-X., Wang L.-L., Cao Q., Jia J.-H.;
RT   "Study of establishment of K562/HHT cell line and reversal of
RT   multidrug resistance by antiprogestin drug mifepristone.";
RL   Chin. J. Pathophysiol. 23:2168-2172(2007).
//